Nordea Investment Management’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$111M Buy
2,610,440
+1,280,403
+96% +$69.5M 0.09% 196
2026
Q1
$82.1M Buy
1,330,037
+1,182,755
+803% +$94.6M 0.08% 216
2025
Q4
$14.1M Buy
147,282
+3,969
+3% +$389K 0.01% 386
2025
Q3
$14M Buy
143,313
+14,262
+11% +$1.48M 0.01% 385
2025
Q2
$13.8M Buy
129,051
+8,535
+7% +$864K 0.01% 362
2025
Q1
$12M Buy
120,516
+981
+0.8% +$98.8K 0.01% 360
2024
Q4
$10.7M Buy
119,535
+7,540
+7% +$664K 0.01% 392
2024
Q3
$9.32M Sell
111,995
-1,166
-1% -$91.9K 0.01% 427
2024
Q2
$8.73M Buy
113,161
+7,065
+7% +$517K 0.01% 426
2024
Q1
$7.29M Buy
106,096
+5,184
+5% +$333K 0.01% 481
2023
Q4
$5.87M Buy
100,912
+5,747
+6% +$307K 0.01% 501
2023
Q3
$5.07M Sell
95,165
-444
-0.5% -$23.3K 0.01% 498
2023
Q2
$5.17M Buy
95,609
+3,142
+3% +$164K 0.01% 509
2023
Q1
$4.63M Buy
92,467
+2,058
+2% +$97K 0.01% 534
2022
Q4
$4.16M Buy
90,409
+342
+0.4% +$14.8K 0.01% 554
2022
Q3
$3.58M Buy
90,067
+1,156
+1% +$46.4K 0.01% 593
2022
Q2
$3.31M Buy
88,911
+11,442
+15% +$466K ﹤0.01% 627
2022
Q1
$3.48M Sell
77,469
-38,216
-33% -$1.66M ﹤0.01% 639
2021
Q4
$4.97M Sell
115,685
-428
-0.4% -$18K 0.01% 588
2021
Q3
$5.12M Hold
116,113
0.01% 603
2021
Q2
$4.96M Buy
116,113
+34,087
+42% +$1.43M 0.01% 612
2021
Q1
$3.19M Sell
82,026
-292,017
-78% -$11.1M ﹤0.01% 640
2020
Q4
$13.4M Buy
374,043
+42,160
+13% +$1.52M 0.02% 334
2020
Q3
$12.6M Sell
331,883
-210,659
-39% -$8.12M 0.02% 315
2020
Q2
$18.6M Buy
542,542
+268,673
+98% +$9.68M 0.02% 330
2020
Q1
$8.62M Sell
273,869
-5,336
-2% -$208K 0.02% 330
2019
Q4
$12.5M Buy
279,205
+1,647
+0.6% +$68.9K 0.03% 319
2019
Q3
$11.3M Buy
277,558
+831
+0.3% +$35.2K 0.02% 325
2019
Q2
$11.9M Buy
276,727
+38,033
+16% +$1.46M 0.03% 328
2019
Q1
$9.16M Buy
238,694
+163,640
+218% +$6.25M 0.02% 405
2018
Q4
$2.65M Sell
75,054
-16,260
-18% -$590K 0.01% 777
2018
Q3
$3.52M Sell
91,314
-11,848
-11% -$414K 0.01% 770
2018
Q2
$3.37M Buy
103,162
+5,795
+6% +$175K 0.01% 565
2018
Q1
$2.66M Buy
97,367
+3,592
+4% +$97.6K 0.01% 691
2017
Q4
$2.33M Buy
93,775
+11,869
+14% +$327K 0.01% 667
2017
Q3
$2.39M Buy
81,906
+7,484
+10% +$207K 0.01% 574
2017
Q2
$2.06M Buy
74,422
+701
+1% +$18.6K 0.01% 570
2017
Q1
$1.83M Sell
73,721
-362
-0.5% -$8.8K ﹤0.01% 570
2016
Q4
$1.6M Buy
74,083
+6,040
+9% +$132K ﹤0.01% 565
2016
Q3
$1.62M Buy
68,043
+7,124
+12% +$170K ﹤0.01% 520
2016
Q2
$1.42M Buy
60,919
+9,061
+17% +$196K ﹤0.01% 488
2016
Q1
$975K Hold
51,858
﹤0.01% 551
2015
Q4
$956K Hold
51,858
﹤0.01% 548
2015
Q3
$851K Sell
51,858
-740
-1% -$12.6K ﹤0.01% 473
2015
Q2
$931K Hold
52,598
﹤0.01% 464
2015
Q1
$934K Sell
52,598
-201,982
-79% -$3.19M ﹤0.01% 470
2014
Q4
$3.37M Buy
254,580
+91,994
+57% +$1.18M 0.01% 286
2014
Q3
$1.92M Sell
162,586
-7,292
-4% -$91.8K 0.01% 376
2014
Q2
$2.17M Buy
169,878
+7,196
+4% +$93.6K 0.01% 418
2014
Q1
$2.2M Buy
162,682
+3,825
+2% +$50.2K 0.01% 409
2013
Q4
$1.91M Buy
158,857
+8,393
+6% +$99.2K 0.01% 444
2013
Q3
$1.77M Hold
150,464
0.01% 464
2013
Q2
$1.4M Buy
+150,464
New +$1.28M 0.01% 514

Other funds holding BSX

Nordea Investment Management's BSX Position: Q2 2026 in Review

Nordea Investment Management increased its Boston Scientific (BSX) stake by 96% in Q2 2026, buying an estimated $69.5M and bringing the position to 2,610,440 shares worth $111M. The position accounts for 0.09% of the portfolio, ranked #196.

Nordea Investment Management first reported a position in BSX in Q2 2013 and has held it in 53 quarters since. 1,484 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Nordea Investment Management held 2,610,440 shares of Boston Scientific worth $111M as of Q2 2026.
  • Nordea Investment Management bought 1,280,403 Boston Scientific shares in Q2 2026, an estimated $69.5M.
  • Boston Scientific made up 0.09% of Nordea Investment Management's portfolio in Q2 2026, its #196 holding.
  • Nordea Investment Management first reported a position in Boston Scientific in Q2 2013 and has held it in 53 quarters since.
  • 1,484 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Nordea Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.